PPARG and atherosclerosis: In vivo, Bouhlel et al. [34] showed a significant upregulation of PPARγ expression in PBMCs of subjects after 2 months of 45 mg/day pioglitazone (TZD) treatment in patients with severe atherosclerosis, although expression of the PPARγ dependent genes, CD136 and mannose receptor, did not change.